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and Eric D. Endean, MD, Lexington, Ky
Background: The optimal therapy for TransAtlantic Societal Consensus (TASC) type C femoropopliteal lesions remains
a critical issue in the treatment of infrainguinal occlusive disease. The purpose of this study was to evaluate the outcome
of limbs with TASC C femoropopliteal lesions and critical limb ischemia treated with the FoxHollow SilverHawk
atherectomy catheter.
Methods: From September 2004 to September 2005, 18 consecutive femoropopliteal procedures performed in 17 limbs
in 16 patients were reviewed. Demographic data, baseline angiographic findings, and indications for the procedures were
recorded. Clinical outcomes including symptom resolution and limb salvage were determined for the 17 primary
procedures. Hemodynamic improvement was compared by using the paired Student t test. Stenosis-free patency was
determined by the Kaplan-Meier method.
Results: The mean age was 72.5 years (range, 47-88 years). Fifty percent of the patients had four or more of the following
risk factors: hypertension, diabetes, tobacco use, hyperlipidemia, renal insufficiency, and coronary artery disease. The
indication was tissue loss in 13 limbs and rest pain in 4. All patients had a second level of disease, either inflow or
tibial/pedal, which was treated concurrently when appropriate. Initial resolution of symptoms was achieved in 12 limbs,
and partial healing was achieved in 2 others. Early amputation was necessary in the remaining three patients, but this was
likely due to severe inframalleolar disease and advanced forefoot ischemia at the time of presentation. Five patients have
remained symptom-free without restenosis at a mean follow-up of 6 months. Two patients have required late amputation
for hemodynamic failure. The ankle-brachial index improved from 0.39 0.08 (mean SEM) before surgery to 0.75
0.08 in the immediate postoperative period (P  .02). However, it returned toward baseline at 6 months after surgery,
with a mean of 0.48  0.07. Stenosis-free patency of the femoropopliteal segment was 22% at 12 months.
Conclusions: Peripheral atherectomy can achieve good early clinical and hemodynamic success in patients with TASC C
lesions and critical limb ischemia. However, mid-term restenosis rates are high in this challenging cohort of patients.
(J Vasc Surg 2006;44:503-9.)The objective of the TransAtlantic Societal Consensus
(TASC) was to provide standardized recommendations for
the treatment of lower extremity atherosclerotic occlusive
disease by the leading vascular societies of North America
and Europe.1 As part of their consensus statement, the
importance of stratification of patients based on angio-
graphic extent of disease and indication for intervention
was recognized. One of the critical issues identified was the
optimal treatment for TASC C lesions, defined as a single
stenosis or occlusion longer than 5 cm or multiple stenoses
or occlusions, each 3 to 5 cm, with or without heavy
calcification.
The gold standard for lower extremity revascularization
has long been bypass with autologous saphenous vein.
Patency rates of the femoral to below-knee popliteal artery
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Advances in endovascular technology have provided other
options with decreased morbidity and mortality compared
with vein bypass. However, the clinical efficacy of these
procedures in more advanced disease remains unproven.
One of the more recent modalities on the market is a
new form of percutaneous atherectomy catheter, the Fox-
hollow Silverhawk (Redwood City, Calif). Despite the
catheter’s widespread use, there are currently very few
published data addressing the late clinical efficacy of this
device. The largest study on the femoropopliteal segment
reported a 6-month stenosis-free patency of 73% in de novo
lesions.3 However, the study involved more favorable le-
sions (2.5-7 mm long), and the indication for intervention
was claudication in 90% of the patients. The purpose of this
study was to evaluate outcomes with the Foxhollow Silver-
hawk atherectomy catheter for limb salvage in patients with
TASC C lesions and critical limb ischemia.
METHODS
A retrospective chart review was performed at the Uni-
versity of Kentucky and the adjoining Veterans Affairs
Medical Center to identify all patients who underwent
femoropopliteal atherectomy between September 2004
and September 2005. Data regarding age, sex, diabetes,
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onary artery disease and the indication for the procedure
were recorded. Preprocedural angiograms for each patient
were reviewed to determine the TASC lesion type and
weighted runoff scores.4 The presence of concurrent inflow
disease was noted as well. Weighted runoff scores were used
to provide a standardized quantification of distal disease.
The method takes into account both the amount of disease
and the contribution of each individual vessel to overall
runoff in determining a total score. For reference, a score of
1 is normal, and 10 signifies that all 3 runoff vessels are
occluded throughout their length.
Patient cohort. Eighteen femoropopliteal atherec-
tomy procedures on 17 limbs in 16 patients were identified.
One patient underwent bilateral atherectomy 2 months
apart. One limb underwent a second atherectomy for reste-
nosis. Only the 17 primary procedures were included in the
hemodynamic and patency outcomes analysis. The age of
patients ranged from 47 to 88 years, with a mean of 72.5
years. Comorbidities were prevalent: 50% of the patients
presented with four or more atherosclerotic risk factors.
Eleven of the 16 patients had no available saphenous vein.
The indication for all procedures was critical limb ischemia.
Four procedures were for rest pain. The remainder of
procedures were performed for tissue loss. Complete de-
mographics are summarized in Table I.
Procedure. All procedures were performed in the op-
erating room by using an OEC 9800 C-arm (GE Health-
care, Waukesha, Wis) except one that was performed in the
cardiac catheterization laboratory. Percutaneous or open
femoral access was obtained in each limb for an on-table
preatherectomy arteriogram. For percutaneous access, a 7F
sheath was used in an antegrade technique, although a
retrograde crossover technique can also be used. The de-
vice consists of a battery-powered rotating cutting assembly
Table I. Clinical characteristics of patients undergoing
femoropopliteal atherectomy
Variable n (%)
Male 15 (94%)
Risk factors
Hypertension 16 (100%)
Diabetes 11 (69%)
Smoking 3 (19%)
Hyperlipidemia 6 (38%)
Renal insufficiency/dialysis 2 (12%)/7 (44%)
CAD 11 (69%)
No. risk factors
0 0
1 1 (6%)
2 3 (19%)
3 4 (25%)
3 8 (50%)
Indication for procedure
Rest pain 4 (24%)
Tissue loss 13 (76%)
CAD, Coronary artery disease.in a tubular housing and tracks over a 0.014-inch guidewirein a monorail fashion. A lever on the extracorporeal proxi-
mal portion of the catheter simultaneously turns on the
cutting assembly and deflects the cutter housing to expose
the blade against the wall of the vessel. As the catheter is
advanced, the cutter assembly shaves atheroma into the
collecting nose cone of the tubular housing. For our study,
atherectomy was performed on each stenotic area noted on
the arteriogram by using multiple passes along different
quadrants. Completion arteriography was then performed
to document the result and the need for further atherec-
tomy. All patients received systemic anticoagulation before
vascular manipulation. Adjuvant procedures were per-
formed at the discretion of the surgeon. An embolic pro-
tection device was not used. All patients received antiplate-
let therapy (325 mg of aspirin or 75 mg of clopidogrel)
before and after surgery, at the discretion of the attending
surgeon.
Technical success was considered the absence of any
residual stenosis of 30% diameter or greater. Clinical out-
come data collected included preintervention, postinterven-
tion, and mid-term follow-up ankle-brachial index (ABI),
limb salvage, and resolution and/or recurrence of symp-
toms. All patients with suspected stenosis (recurrence of
symptoms or decrease in ABI) underwent further imaging
to confirm the presence and site of recurrence. Data analysis
was performed by using paired Student t tests and Kaplan-
Meier analysis.
RESULTS
Angiographic findings and operative results. All
limbs had TASC C femoropopliteal lesions and at least one
other level of disease. In five limbs, the second level was
primarily inflow disease. In the other 12, it was primarily
tibial/pedal disease. Angiographic findings are summarized
in Table II.
All patients with inflow disease underwent concurrent
inflow procedures. These included three iliac atherecto-
mies, one femoral-femoral bypass revision, and one iliac
angioplasty and endoluminal aortic aneurysm repair. Of the
Table II. Angiographic findings of patients undergoing
femoropopliteal atherectomy
Variable n (%)
TASC C 17 (100%)
Weighted runoff score
9 4 (22%)
8.5 1 (6%)
8 2 (11%)
7.5 2 (11%)
7 1 (6%)
6.5 3 (17%)
6 1 (6%)
5 1 (6%)
1 2 (11%)
Inflow disease 5 (28%)
TASC, TransAtlantic Societal Consensus.12 limbs whose second level of disease was primarily tibial/
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These included five atherectomies and one angioplasty of
more proximal tibial disease. The remaining six patients
had significant distal (inframalleolar) disease or rest pain (ie,
pulsatile flow to the foot was not the objective).
Technical success was achieved in 16 (88%) of the 18
femoropopliteal atherectomy procedures. Two procedures
were considered technical failures because of residual ste-
nosis after repeated passes of the Silverhawk catheter. In
both cases, the residual stenosis was relieved with angio-
plasty. No case required adjuvant stent placement. The only
complication of femoropopliteal atherectomy was a single
case of atheroembolism, which was successfully treated
with atherectomy of the embolized plaque. However, it
should be noted that one iliac artery ruptured during
concurrent atherectomy and was treated with a covered
stent.
Clinical outcome. Twelve of the 17 limbs had initial
resolution of symptoms (ie, resolution of rest pain, healing
of ulcer, or healing of a minor amputation). Two others
have stable or healing wounds. The three remaining pa-
tients required early (within 1 month) below-knee ampu-
tation for progressive forefoot necrosis. All three of these
patients presented with advanced forefoot ischemia and had
severe inframalleolar disease. Atherectomy was offered only
as a last-chance, minimally invasive attempt at limb salvage.
Of the 12 limbs that experienced initial resolution of
their symptoms, 7 have remained symptom free at an
average follow-up of 6 months (range, 1-12 months).
However, two of these have documented restenosis of their
femoropopliteal segment that we have elected to follow up
conservatively. Five patients developed recurrent symptoms
after initial resolution and were found to have restenosis.
Two underwent attempted endovascular reintervention
(one atherectomy and one cryoplasty) and subsequently
required below-knee amputation. One underwent bypass
and has healed. Two are refusing reintervention.
Of the two patients with healing/stable wounds, one
has restenosis but has not undergone reintervention sec-
ondary to multiple medical comorbidities. The overall limb
salvage was 70%, whereas in the 13 patients with tissue loss,
it was 62%. Complete clinical outcome is summarized in
Fig 1.
Hemodynamic and patency outcome. Coinciding
with the clinical findings, ABI improved from 0.39  0.08
(mean  SEM) before surgery to 0.75  0.08 in the early
postoperative period (P  .02). However, late ABI at an
average of 6 months after surgery returned toward baseline,
with a mean of 0.48  0.07 (Fig 2).
Eight patients have developed site-specific restenosis of
the treated femoropopliteal segment (Fig 3). Restenosis
tended to occur between 4 and 9 months after atherec-
tomy. Stenosis-free primary patency by Kaplan-Meier esti-
mate was 22% at 12 months (Fig 4).
DISCUSSION
In general, the authors have taken a fairly conservative
approach to femoropopliteal occlusive disease. At our insti-tution, most isolated TASC A and B lesions can be man-
aged nonoperatively because these patients most often
present with nondisabling claudication. TASC D lesions
with critical limb ischemia are usually treated with bypass,
per TASC recommendations. Like others, we are still
searching for the optimal treatment of TASC C lesions. By
design, atherectomy seemed to be an ideal minimally inva-
sive alternative to bypass in these patients because extensive
multifocal stenoses can be treated with a single catheter and
without the use of stents. Our initial results were quite
positive, with most patients experiencing a marked im-
provement in their hemodynamic and clinical parameters.
In fact, it quickly became our treatment of choice in this
subset of patients. However, the high incidence of recur-
rent symptoms and restenosis has dampened our early
enthusiasmwith the realization that this particular subset of
patients will continue to present significant challenges to
the endovascular treatment of peripheral vascular disease.
One of the reasons that this group is so challenging is
Fig 1. Clinical outcomes of 17 limbs treated primarily with fem-
oropopliteal atherectomy.
Fig 2. Average ankle-brachial index in patients undergoing fem-
oropopliteal atherectomy for critical limb ischemia (*P  .05
compared with preoperative results). Pre, Before surgery; Post,
after surgery.that femoropopliteal stenosis, in and of itself, is unlikely to
rrent
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recognized that true critical limb ischemia is usually associ-
ated with multilevel occlusive disease. Our results certainly
bear this out. All of our patients had at least one other level
of disease, either aortoiliac (inflow) disease or tibial-pedal
disease. This second level of disease can have a significant
effect on outcome. Tibial-pedal disease seems to be the
more ominous of the two. There is a considerable body of
evidence showing that poor runoff is associated with a
higher failure rate after femoropopliteal angioplasty.2 Sim-
ilar findings have been noted for bypass procedures.5
It is interesting to note that we did not see an improve-
Fig 3. Angiography demonstrating severe recu
Fig 4. Cumulative stenosis-free patency of femoropopliteal le-
sions treated with atherectomy, by the Kaplan-Meier method.ment in the durability of atherectomy in our subset ofpatients whose second level of disease was aortoiliac, rather
than tibial-pedal. In fact, all five of the patients who under-
went a concurrent inflow procedure had site-specific reste-
nosis of their femoropopliteal atherectomy. All of these
patients have achieved limb salvage to date, but that is likely
due to the durability of their inflow procedure.
Conversely, we believe that the data on our patients
with severe tibial-pedal disease does confirm its negative
effect, at least on clinical outcome. The three patients who
required early amputations presented with gangrene and
minimal demonstrable flow below the ankle on preopera-
tive angiography. It was our hope in these patients that
healing of a forefoot amputation could be achieved with
atherectomy, similar to results that have been observed in
bypass to the peroneal6 or isolated popliteal7 artery. Al-
though these patients had an adequate technical result from
atherectomy, it was not enough to heal their forefoot
amputations. Considering the technical success of the
atherectomy procedure, the authors believe that it is un-
likely that a bypass would have significantly improved the
pedal perfusion (and, therefore, the ultimate clinical result)
in these three patients. Furthermore, all three had signifi-
cant comorbidities, and only one had a usable saphenous
vein. It should be noted that there were two other patients
in our cohort with similar presentation who did achieve
early limb salvage.
The two patients who required late amputation from
hemodynamic failure also presented with runoff compro-
disease 6 months after successful atherectomy.mise. Their primary runoff lesions were in the more proxi-
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atherectomy to improve outflow. Likewise, it should be
noted that there were three other patients in our cohort
with tissue loss who underwent concurrent proximal tibial
atherectomy and have achieved limb salvage without reste-
nosis to date. Because of the small number of patients in our
cohort, it is difficult to draw any conclusions from subset
analysis other than an expected general trend toward limb
loss in patients with significant tibial-pedal disease.
Perhaps the most important concern generated by the
results, though, involves the overall durability of peripheral
atherectomy. Although our study represents a relatively
limited experience with the Silverhawk catheter, the initial
favorable hemodynamic response seen in our cohort argues
against an inadequate debulking at the time of the proce-
dure as a possible etiology for this poor durability. We
found the catheter to be very easy to use, with a minimal
learning curve. Rather, the time frame and the diffuse
restenosis demonstrated on angiography implicate intimal
hyperplasia as the etiology of the late failure.
Unfortunately, as mentioned in the introduction, there
are very few other peer-reviewed, published data objectively
evaluating the durability of the Silverhawk catheter, provid-
ing only 6-month patency data primarily in claudicators
with more favorable lesions. It is interesting to note that
our stenosis-free patency at 6 months was actually fairly
similar to the 73% reported in that study,3 thus underscor-
ing the importance of longer follow-up when any modality
is evaluated.
There is, conversely, a considerable body of evidence
regarding previous iterations of atherectomy catheters. The
most relevant predecessor is the Simpson atherectomy cath-
eter. Foxhollow received a 510(k) approval from the Food
andDrug Administration tomarket the Silverhawk catheter
by demonstrating that the catheter had a mechanism of
action similar to that of the previously approved Simpson
atherectomy catheter. That catheter, like the Silverhawk,
enjoyed early popularity. However, subsequent prospec-
tive, randomized trials showed similar or higher restenosis
rates with the Simpson AtheroCath compared with angio-
plasty alone.8-10 There have been multiple other iterations
of peripheral atherectomy devices as well, most notably the
Transluminal Extraction Catheter, the Trac-Wright Cath-
eter, and the Auth Rotablator. These too ultimately failed
to achieve acceptance because of high restenosis rates and
increased complications, such as atheroembolism, when
compared with angioplasty.11-14 Other forms of femoro-
popliteal debulking procedures have suffered from in-
creased restenosis rates as well.15
With regard to atheroembolism, we experienced only
one case of macroscopic embolus, which we were able to
clear with additional atherectomy. We cannot comment on
microatheroembolism because we did not use an embolic
protection device during these procedures. However, other
recent studies have observed this phenomenon with the
Silverhawk, thus suggesting that an embolic protection
device may be an appropriate adjunct to this procedure.16When our results are compared with other forms of
treatment, it is important to recognize that this study
represents a very select patient population. That is, these
patients presented with severe, diffuse femoropopliteal ste-
nosis and critical limb ischemia. Most patients had gan-
grene or tissue loss. There was also a high incidence of
diabetes and renal insufficiency, both of which have been
shown to have a negative effect on endovascular interven-
tions.17 As such, they represent the most challenging pa-
tient population for endovascular management of infrain-
guinal occlusive disease.
In contrast, most studies on infrainguinal endovascular
intervention involve patients with claudication and more
favorable TASC lesions. The variability in results based on
patient selection alone is substantial and must be taken into
account when results are compared across studies. In addi-
tion, it is important to recognize that outcome reporting
varies widely as well. Clinical outcomes, such as freedom
from target lesion revascularization, will have improved
results compared with radiographic outcomes. As an exam-
ple, because five of our patients with restenosis have not
undergone reintervention for various reasons, our target
lesion revascularization was actually only 18%. The authors
do not recommend this outcome to be used as a primary
end point for peripheral interventions because it can be
highly misleading, and there is ready availability of more
objective, noninvasive measures. That being said, as tech-
niques and technologies improve, there is an increasing
body of data on critical limb ischemia in more advanced
infrainguinal lesions.
The mainstay of femoropopliteal endovascular inter-
vention through the years has been angioplasty. As such,
most studies on endovascular intervention for more ad-
vanced femoropopliteal disease involve this modality. Mid-
term stenosis-free patency after femoropopliteal angio-
plasty for critical limb ischemia has been reported in the
range of 15% to 50%.18-22 Thus, our results, in fact, seem
comparable to those of angioplasty in this specific subgroup
of patients.
Several recent studies on other modalities have shown
promise in improving the durability of endovascular ther-
apy for femoropopliteal occlusive disease. These modalities
include nitinol stents,23 covered stents,24 drug-eluting
stents,25 and cryoplasty.26 Unfortunately, these studies
were performed primarily in claudicators with less extensive
disease and are not applicable for comparison to our results.
On the basis of current available data, then, we must
conclude that bypass with autologous saphenous vein re-
mains the gold standard in terms of durability in patients
with critical limb ischemia and advanced femoropopliteal
occlusive disease. Strong consideration for bypass as pri-
mary therapy should be made in patients who are ideal
candidates for the procedure. Unfortunately, many patients
are far from ideal candidates for bypass. In our own cohort,
multiple comorbidities were the rule, and saphenous vein
was often not available. Perioperative mortality rates from
infrainguinal vein bypass have been reported in the range of
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10% to 30% of patients.28-30
Atherectomy offers a technically feasible alternative in
these patients. Despite its high restenosis rate, mid-term
limb salvage seems acceptable for this very-high-risk patient
population. Thus, the device may be an appropriate option
in patients with limited life expectancy and critical limb
ischemia. In addition, like many endovascular procedures,
atherectomy does not necessarily preclude future bypass,
perhaps justifying a more aggressive approach with this
percutaneous procedure. However, close surveillance with
appropriate reintervention is recommended in an attempt
to improve results. Further studies are needed to determine
whether other forms of endovascular treatment will offer
improved results and to define the role of this catheter in
the treatment of claudication.
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